Par Health Argatroban Injection Wrongful Death Lawsuit Lawyers

Par Health Recalls Argatroban Injection Over Dangerous Particulate Contamination

What Parker Waichman LLP Found

• Nationwide recall: Par Health recalled 22 lots of Argatroban Injection distributed to hospitals and wholesalers throughout the United States.
• Multiple contaminants: Identified materials included cellulose, polystyrene, polyethylene terephthalate, stopper material, and potentially stainless steel.
• Potentially fatal complications: Contaminated injections may cause pulmonary emboli, vascular blockages, tissue death, organ damage, or vein inflammation.
• Potential lawsuits: Patients who develop injuries linked to contaminated medication may have grounds to investigate pharmaceutical product liability claims.

Par Health has announced a voluntary nationwide recall of 22 lots of Argatroban Injection, 250 mg/2.5 mL, after particulate contamination was identified in the injectable medication. According to the recall announcement published by the U.S. Food and Drug Administration (FDA) on October 14, 2026, the foreign material included plastic particles, material associated with vial stoppers, and potentially stainless steel. These contaminants raise serious safety concerns because Argatroban is administered directly into the bloodstream, potentially allowing foreign particles to circulate through blood vessels and reach vital organs. Depending on the size, composition, and location of the particles, contaminated intravenous medication may cause vascular obstruction, inflammation, tissue damage, or other serious medical complications. Patients receiving this medication often have complex medical conditions that make additional complications particularly dangerous.

The recall affects products distributed nationwide, creating potential exposure concerns for hospitals, pharmacies, and other healthcare facilities that administer intravenous anticoagulants. Although Par Health had not reported injuries or deaths associated with the recall as of the announcement, the company’s risk assessment identified the possibility of severe or life-threatening complications if contaminated medication is administered. The absence of reported injuries does not eliminate the need to investigate suspected adverse reactions, particularly when patients experience unexplained respiratory distress, cardiovascular instability, or organ dysfunction following treatment.

The FDA publication does not establish that every recalled vial contains particulate matter or that every patient who received Argatroban suffered an injury. Nevertheless, patients who experienced serious complications following administration of an affected lot may have grounds to investigate whether contamination contributed to their condition.

Par Health Argatroban Injection Recall Information

The recall involves the injectable anticoagulant Argatroban, supplied at a concentration of 250 mg/2.5 mL. The affected products were distributed throughout the United States and include 22 manufacturing lots.

Healthcare facilities should review the manufacturer’s official recall notice to identify the affected lot numbers and determine whether recalled medication remains in their inventories. The recall applies to specified lots rather than necessarily every Argatroban product available in the United States.

Patients should not discontinue prescribed anticoagulant treatment without medical guidance. Argatroban is frequently used in circumstances where interrupting anticoagulation can itself create serious health risks.

Why Argatroban Is Used to Treat Patients With Dangerous Blood Clotting Conditions

Argatroban is an intravenous anticoagulant that works by directly inhibiting thrombin, an enzyme involved in blood clot formation. By interfering with thrombin activity, the medication helps prevent the formation and progression of dangerous blood clots.

One important use of Argatroban is the treatment or prevention of thrombosis in patients with heparin-induced thrombocytopenia (HIT). This potentially serious immune-mediated condition can occur when a patient develops an adverse reaction to heparin, another commonly administered anticoagulant. HIT can produce a reduction in platelet counts while paradoxically increasing the risk of dangerous blood clot formation.

Argatroban may also be used during percutaneous coronary intervention in certain patients with HIT or a history of the condition. These procedures involve catheter-based treatment of narrowed or blocked coronary arteries and require careful anticoagulation management.

Patients receiving Argatroban may already be hospitalized, critically ill, recovering from surgery, or undergoing treatment for cardiovascular disease. Because the medication is delivered intravenously, particulate contamination presents a different concern from impurities in medications taken orally. Foreign material introduced into a vein may enter the circulation without passing through the body’s normal gastrointestinal barriers.

How Particulate Contamination Can Cause Serious Injuries

Blood Vessel Blockages and Pulmonary Complications

One of the principal concerns associated with contaminated intravenous medication is the possibility that foreign particles will obstruct small blood vessels. Material entering the venous circulation typically travels toward the right side of the heart and then into the pulmonary circulation.

Particles may become trapped in smaller pulmonary vessels, potentially disrupting blood flow and contributing to inflammation or other pulmonary complications. The clinical effects depend on factors including particle size, the amount administered, and the patient’s underlying medical condition.

The recall announcement identifies pulmonary embolic complications as a potential hazard. Particulate embolization is not necessarily the same as a conventional pulmonary embolism caused by a blood clot, but both can interfere with pulmonary circulation.

Patients experiencing significant pulmonary complications may develop sudden shortness of breath, chest discomfort, low oxygen levels, or cardiovascular instability. Severe cases may require emergency respiratory support, intensive care, and additional diagnostic testing.

Organ Damage and Inflammatory Reactions

Foreign particles introduced through an intravenous medication can provoke inflammatory responses or interfere with normal tissue perfusion. Depending on the affected circulation and the patient’s condition, complications may include localized vascular injury, inflammation, or damage to organs dependent on adequate blood supply.

Particles originating from plastic, stopper material, or metal may differ in their physical and biological effects. The presence of potentially metallic material raises additional questions about particle composition, manufacturing conditions, and whether the contamination could have been prevented.

Patients with impaired cardiovascular function, respiratory disease, or other serious medical conditions may be particularly vulnerable to additional physiological stress. However, a suspected adverse event requires medical evaluation before it can be attributed to contaminated medication.

Emergency Treatment and Prolonged Hospitalization

A serious reaction following contaminated intravenous medication may require emergency intervention, additional imaging, specialist consultations, and prolonged hospital monitoring. Patients who develop respiratory or cardiovascular complications may need oxygen therapy, mechanical ventilation, or intensive care.

When organ damage occurs, recovery may involve rehabilitation, continuing medication, repeat medical testing, or treatment for permanent functional limitations.

These consequences can be especially burdensome for individuals who were already hospitalized for another medical condition. An additional complication may substantially increase medical expenses, extend recovery time, and interfere with the patient’s ability to return to normal activities.

FDA Recall Identifies 22 Affected Argatroban Injection Lots

The FDA-posted announcement identifies two National Drug Code (NDC) numbers associated with the recalled medication. The affected products were distributed by Par Pharmaceutical or Endo USA, predecessor companies to Par Health USA, LLC.

The affected lots were distributed to wholesalers and hospitals nationwide between December 30, 2024, and May 5, 2026. Par Health instructed wholesale distributors and hospital pharmacies to stop using and distributing the recalled products and arrange their return.

Potential Argatroban Injection Contamination Lawsuits Against Responsible Companies

Patients who suffered serious injuries after receiving contaminated Argatroban Injection may have grounds to investigate a pharmaceutical product liability lawsuit. Potential claims could involve manufacturing defects, inadequate quality controls, negligence, or other legally actionable conduct.

A manufacturing defect claim generally focuses on whether a medication departed from its intended specifications and became unreasonably dangerous. The presence of unintended plastic, stopper, or metal particles in an intravenous medication may raise questions about manufacturing procedures, packaging integrity, inspection practices, and quality assurance.

However, the existence of a recall does not automatically establish that a manufacturer is legally responsible for an individual patient’s injuries. Attorneys must determine whether the patient received an affected product, whether contamination was present, and whether the suspected defect caused or contributed to the patient’s medical complications.

Frequently Asked Questions About Argatroban Injection Recall Lawsuits

Can I File a Lawsuit if I Received Recalled Argatroban Injection?

Receiving medication from a recalled lot does not automatically establish eligibility for compensation. However, patients who experienced serious complications after receiving affected Argatroban Injection may have grounds to investigate a pharmaceutical product liability claim. Attorneys would examine medication administration records, lot identification information, medical findings, and the timing of the patient’s symptoms. A successful lawsuit generally requires proof that a legally actionable product defect caused or contributed to an identifiable injury. The FDA-posted recall provides important safety information, but each claim requires an independent assessment.

What Injuries Could Support an Argatroban Contamination Lawsuit?

Potential injuries include pulmonary vascular obstruction, vein inflammation, tissue damage, organ injury, and other serious complications medically linked to particulate contamination. The manufacturer’s announcement identifies these conditions as possible consequences of administering contaminated medication. However, the presence of a medical complication after Argatroban treatment does not necessarily establish that the medication caused it. Patients receiving anticoagulants may already face significant clotting risks. Medical records, imaging studies, and physician opinions may help determine whether a suspected injury is attributable to contaminated medication rather than an underlying condition.

How Can I Find Out Whether My Hospital Administered Recalled Argatroban?

Patients can request medication administration records and pharmacy dispensing information from the hospital where they received treatment. These records may help identify the manufacturer, product strength, and lot number. The recalled medication was distributed under NDC numbers 42023-182-01 and 42023-182-89, with 22 affected lots. Hospitals may also have inventory and purchasing records that identify which products were available during a particular treatment period. If the lot number is not included in the patient’s chart, additional hospital documentation may be necessary to establish whether an affected product was administered.

How Long Do I Have to File an Argatroban Injection Injury Lawsuit?

Pharmaceutical product liability lawsuits are subject to statutes of limitations that vary by state. The filing deadline may depend on when the injury occurred, when it was discovered, and whether the law recognizes an applicable discovery rule. Some jurisdictions also impose statutes of repose or additional procedural requirements. Patients should not assume that the FDA’s October 14, 2026, publication date determines their filing deadline. Early legal review may help preserve hospital records, identify the medication lot, and determine whether a claim can be filed within the applicable period.

Contact Parker Waichman LLP About a Contaminated Argatroban Injection Lawsuit

Patients receiving intravenous anticoagulants depend on pharmaceutical manufacturers to supply medications that meet appropriate safety and quality standards. When injectable drugs contain foreign particles, the resulting complications can be particularly serious for individuals already receiving treatment for dangerous blood clotting conditions.

If you or a loved one experienced pulmonary complications, vascular obstruction, organ damage, prolonged hospitalization, or another serious injury after receiving Argatroban Injection, you may have grounds to investigate a pharmaceutical product liability claim. Determining whether your treatment involved one of the recalled lots is an important first step.

Parker Waichman LLP is a national personal injury law firm representing individuals and families harmed by allegedly defective or contaminated pharmaceutical products. Our attorneys can review medical documentation, investigate the medication involved, and evaluate whether a product liability claim may be appropriate.

Call Parker Waichman LLP at 1-800-YOUR-LAWYER (1-800-968-7529) for a free consultation. Learn whether you may be entitled to pursue compensation for medical expenses, lost income, pain and suffering, and other damages associated with an allegedly contaminated medication. Regardless of your location or where your injury occurred, our nationwide product injury law firm is ready to assist you.